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Insulin resistance, which plays a key role in the development of diabetes mellitus, is a putative modifiable risk
factor for stroke. The aim of this study was to investigate if markers of insulin resistance were associated with
risk of stroke in the general elderly population. This study was part of the large population-based Rotterdam
Study and included 5,234 participants who were aged 55 years or older and stroke free and diabetes free at
baseline (1997–2001). Fasting insulin levels and homeostasis model assessment for insulin resistance were
used as markers for insulin resistance. Cox regression was used to determine associations between insulin
resistance markers and stroke risk, adjusted for age, sex, and potential confounders. During 42,806 person-
years of follow-up (median: 8.6 years), 366 first-ever strokes occurred, of which 225 were cerebral infarctions, 42
were intracerebral hemorrhages, and 99 were unspecified strokes. Fasting insulin levels were not associated
with risk of any stroke, cerebral infarction, or intracerebral hemorrhage. Homeostasis model assessment for
insulin resistance, which almost perfectly correlated with fasting insulin levels, was also not associated with risk
of stroke or stroke subtypes. In conclusion, in this population-based cohort study among nondiabetic elderly,
insulin resistance markers were not associated with risk of stroke or any of its subtypes.
cerebral infarction; cohort studies; diabetes mellitus; insulin resistance; intracerebral hemorrhage; stroke
Abbreviations: HOMA-IR, homeostasis model assessment for insulin resistance; ln, natural log.
Type 2 diabetes mellitus is a major risk factor for vascu-
lar disease, including stroke (1). Moreover, several studies
suggest that precursor stages of diabetes, such as impaired
fasting glucose and insulin resistance, already increase the
risk of vascular complications (2, 3). However, results from
studies investigating coronary heart disease or vascular
disease either separately or as a composite endpoint may
not apply to stroke. For example, in a large meta-analysis,
fasting glucose levels below the threshold for diabetes
(7.0 mmol/L) were associated with risk of coronary heart
disease but not with risk of stroke (4). The relation between
insulin resistance and stroke risk has been studied less
extensively.
The “gold standard” for quantifying insulin resistance is
the euglycemic hyperinsulinemic glucose clamp technique
(5). Because this method is complicated and impractical for
epidemiologic research, epidemiologic studies use either
the homeostasis model assessment for insulin resistance
(HOMA-IR) index or fasting insulin levels as surrogate
markers for the degree of insulin resistance. Both markers
correlate well with the clamp method (6, 7).
Previous studies have investigated the association
between insulin resistance and stroke, but results remain in-
conclusive. An overview of population-based cohort
studies reporting on the association of the HOMA-IR index
and fasting insulin levels with risk of stroke in people
without diabetes mellitus is given in Tables 1 and 2 (8–14).
Taken together, these studies do not enable us to draw
firm conclusions regarding the association between insulin
resistance and risk of stroke. Apart from conflicting results,
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Table 1. Overview of Prospective Cohort Studies Reporting on the Association Between Fasting Insulin Levels and Risk of Stroke in People Without Diabetes
First Author,
Year
(Reference
No.)
Location
Age
Range,
years
Women,
%
No. at
Risk
Follow-up, years
Outcome No. Continuous HR 95% CI Categorical HR 95% CI Covariates
Mean Median Maximum
Pyorala,
1998 (12)
Finland 34–64 0 970 22.3 Any stroke 70 Per SD 1.07 0.81, 1.41 Quintile 5
vs. Quintiles
1–4
1.54 0.90, 2.62 Age, SBP, smoking,
scapular skinfold
Lakka, 2000
(8)
Finland 42–60 0 1,521 9.4 Any stroke 48 Per pmol/L 1.01 1.00, 1.01 Quartile 1
Quartile 2
Quartile 3
Quartile 4
1.0
1.5
1.1
1.4
Referent
0.5, 4.0
0.4, 3.0
0.5, 4.0
Age, year, SBP,
DBP, smoking,
lipids, BMI, WHR,
alcohol, white
blood cell count,
fibrinogen, VO2
max
Lindahl,
2000 (10)
Sweden 25–64 37 272 12 Any stroke 94 Tertile 1
Tertile 2
Tertile 3
1.0
1.1
2.0
Referent
0.6, 2.3
1.0, 4.0
None
Lawlor, 2007
(9)
United
Kingdom
60–79 100 3,246 4.6 Any stroke 52 ln/SD 1.16 0.83, 1.59 Age, SBP, smoking,
lipids, BMI, WHR,
exercise, SES
Nakamura,
2010 (11)
Japan 35–59 0 2,548 10 Cerebral
infarction
13 ln/SD 1.62 1.03, 2.57 Quartile 4 vs.
Quartile 1
4.01 1.10, 14.67 Age, SBP, blood
pressure-lowering
medications,
smoking, lipids,
waist
circumference,
alcohol, exercise,
lipid-lowering
medications
Rasmussen-
Torvik,
2010 (13)
United
States
45–64 57 12,323 16–18 Cerebral
infarction
445 Quintile 1
Quintile 2
Quintile 3
Quintile 4
Quintile 5
1.00
0.89
1.11
1.10
1.28
Referent
0.63, 1.25
0.82, 1.51
0.80, 1.53
0.92, 1.78
Age, sex, race,
center, SBP,
blood pressure-
lowering
medications,
smoking, BMI, left
ventricular
hypertrophy
Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; ln, natural log; SBP, systolic blood pressure; SD, standard deviation; SES, socioeconomic status;
VO2 max, peak oxygen uptake; WHR, waist/hip ratio.
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Table 2. Overview of Prospective Cohort Studies Reporting on the Association Between the HOMA-IR Index and the Risk of Stroke in People Without Diabetes
First Author,
Year
(Reference
No.)
Location
Age
Range,
years
Women,
%
No. at
Risk
Mean
Follow-up,
years
Outcome No. Continuous HR 95% CI Categorical HR 95% CI Covariates
Tanne, 2009
(22)
Israel 45–74 9 2,938 6.2 Any stroke 172 ln/unit 1.07 0.90, 1.26 Tertile 1
Tertile 2
Tertile 3
1.00
1.07
1.11
Referent
0.72, 1.58
0.74, 1.67
Age, sex, study arm,
hypertension,
smoking, lipids, BMI,
coronary heart
disease
Nakamura,
2010 (11)
Japan 35–59 0 2,548 10 Cerebral
infarction
13 ln/SD 1.59 1.00, 2.54 Quartile 1
Quartile 2
Quartile 3
Quartile 4
1.00
1.40a
1.15a
3.23
Referent
NS
NS
20.82, 12.89
Age, SBP, blood
pressure-lowering
medications, lipids,
waist circumference,
alcohol, smoking,
exercise, lipid-
lowering medications
Rundek,
2010 (14)
United
States
68 64 1,509 8.5 Cerebral
infarction
46 Per SDb 1.04 0.90, 1.19 Quartile 1
Quartile 2b
Quartile 3b
Quartile 4b
1.00
1.88
0.93
3.11
Referent
0.72, 4.87
0.29, 2.95
1.25, 7.76
Age, sex, race, SBP,
DBP, smoking,
lipids, waist
circumference,
alcohol, exercise,
education
Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment for insulin resistance; HR, hazard ratio; ln, natural log; NS, not significant;
SBP, systolic blood pressure; SD, standard deviation.
a Hazard ratios and 95% confidence intervals are plotted on a log scale; values not reported.
b Adjusted for age only.
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most studies were based on relatively small numbers of
events and included middle-aged but not elderly people,
whereas elderly people are at the highest risk of stroke. Fur-
thermore, all studies focused on any stroke or the subtype
cerebral infarction. The association between insulin resis-
tance markers and risk of intracerebral hemorrhage has yet
not been investigated.
The aim of the present study was to investigate in a large
population-based cohort study among elderly people
without diabetes mellitus if the HOMA-IR index and
fasting insulin levels were associated with risk of cerebral
infarction and intracerebral hemorrhage.
MATERIALS AND METHODS
Source population
The present study was part of the Rotterdam Study, an
ongoing prospective population-based cohort study that
focuses on causes and consequences of diseases that are
frequent in the elderly. The rationale and design of the
study have been described extensively elsewhere (15). In
1990, all inhabitants of a well-defined district of the city of
Rotterdam in the Netherlands who were aged 55 years or
older were invited to participate, and 7,983 persons (of
10,215 invitees) agreed. In the year 2000, the cohort was
expanded with 3,011 persons (of 4,472 invitees) who had
reached the age of 55 or had moved into the district since
the start of the study. There were no additional exclusion
criteria; people who were demented or living in a nursing
home were invited as well. All participants underwent a
comprehensive set of baseline examinations that were re-
peated during regular follow-up visits. The study was ap-
proved by an internal review board, and all participants
gave written informed consent to participate in the study.
Measurement of serum glucose and insulin
levels and HOMA-IR
Venous blood samples were taken at the research center
after an overnight fast and stored at −80°C in a number of
5-mL aliquots. Serum glucose levels were determined by
using the glucose hexokinase method within 1 week after
sampling (16). Serum insulin levels were determined in
samples that had been kept frozen from baseline (1997–
2001) until usage in 2008 and were measured on a Roche
Modular Analytics E170 analyzer (Roche Diagnostics
GmbH, Mannheim, Germany) by electrochemilumines-
cence immunoassay technology. This assay does not
cross-react with proinsulin or C-peptide. The intraassay
repeatability of our assay showed a coefficient of variation
of 1.0%. The day-to-day variation of the assay (i.e., inter-
mediate precision) yielded a coefficient of variation of
3.6%. These numbers indicate excellent reliability of the
insulin assay in our study. The following formula was used
to calculate HOMA-IR: [fasting insulin (mU/L) × fasting
glucose (mmol/L)] / 22.5 (7).
Definition of diabetes mellitus
Diabetes mellitus was defined as a fasting serum glucose
level of ≥7.0 mmol/L and/or the use of blood glucose-low-
ering drugs.
Assessment of stroke
Stroke was defined according to World Health Organiza-
tion criteria as a syndrome of rapidly developing clinical
signs of focal (or global) disturbance of cerebral function,
with symptoms lasting 24 hours or longer or leading to
death, with no apparent cause other than of vascular origin
(17). History of stroke at baseline was assessed during the
baseline interview and verified by review of medical
records. After enrollment, participants were continuously
monitored for incident stroke by use of the following strate-
gies. General practitioners are the gatekeepers of our
health-care system; they collect and register all medical
events and hospital visits occurring from birth to death.
Our study participants were all aligned to a general practi-
tioner. Moreover, our study database was electronically
coupled to the general practitioners’ databases, continuously
monitoring medical records for reported stroke events. Fur-
thermore, at regular intervals, well-trained research assis-
tants visited these general practitioners. Nursing home
physicians’ files and files from general practitioners of par-
ticipants who moved out of the district were checked on a
regular basis as well. Additional information was obtained
from hospital records. The records were screened for the
occurrence of stroke events or stroke-like symptoms. If
stroke-like events or stroke-like symptoms were found, the
information was collected, reviewed by a research physi-
cian, and verified by an experienced stroke neurologist. If a
stroke was diagnosed, it was further classified as cerebral
infarction or intracerebral hemorrhage on the basis of neu-
roimaging reports. If neuroimaging was lacking, a stroke
was classified as unspecified. Subarachnoid hemorrhages
were not considered stroke events.
Participants were followed from study entry to stroke,
death, last health status update when they were known to be
stroke free, or January 1, 2009, whichever came first. At
study closeout, the stroke status was unknown for 17% of
participants. If the date “last known to be stroke free” was
earlier than January 1, 2009, the follow-up time was cen-
sored at that particular date. These participants contributed
person-years only until the day they were last known to be
stroke free. Completeness of follow-up, calculated by divid-
ing the sum of observed person-years by the sum of poten-
tial person-years × 100%, was 97.6% (18).
Other measurements
Trained research physicians visited all participants at
home for standardized questionnaires about their health
status and medical history, including questions about
current medication use and cigarette smoking behavior.
Subsequently, all participants visited the research center
twice for physical examination and blood sampling. Blood
pressure was calculated as the average of 2 measurements
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at the right brachial artery with a random-zero sphygmom-
anometer after 5 minutes of rest while the subject was in a
sitting position. Hypertension was defined as a diastolic
blood pressure of ≥90 mm Hg and/or a systolic blood pres-
sure of ≥140 mm Hg, and/or the use of blood pressure-low-
ering medication (19). Fasting serum total cholesterol, high
density lipoprotein cholesterol, and triglyceride levels were
measured by using enzymatic colorimetric methods
(Hitachi Analyzer; Roche Diagnostics). Von Willebrand
factor antigen was determined with an in-house enzyme-
linked immunosorbent assay, using polyclonal rabbit anti-
human von Willebrand factor antibodies (DakoCytomation,
Glostrop, Denmark) for catching and tagging (20). Body
mass index was calculated as weight (kg)/height (m)2. The
waist/hip ratio was calculated by dividing the waist circum-
ference (cm) by the hip circumference (cm).
Population for analysis
The present analyses were based on participants of the
third survey of the 1990 subcohort (n = 5,990) and partici-
pants of the first survey of the 2000 subcohort (n = 3,011).
Of this pooled cohort of 9,001 participants, 8,530 persons
were stroke free at baseline and had given written informed
consent for the collection of follow-up data from general
practitioners. Of these 8,530 persons, we excluded 2,661
persons due to the following reasons: death, refusal,
or physical inability (n = 1,883); failure of blood draw or
storage (n = 479); or nonfasting state (n = 299). This resulted
in 5,869 persons, of whom additionally 635 were excluded
for prevalent diabetes. The final population for analysis
hence included 5,234 participants.
Statistical analysis
We estimated pairwise Pearson correlation coefficients to
determine the strength of the linear relations among fasting
glucose levels, fasting insulin levels, and the HOMA-IR
index. Insulin levels and the HOMA-IR index were natural
log transformed because of nonnormality of their distribu-
tions. Cox proportional hazards regression was used to cal-
culate hazard ratios and 95% confidence intervals for the
associations between fasting insulin levels, the HOMA-IR
index, and fasting glucose levels and the risk of stroke and
the stroke subtypes, cerebral infarction and intracerebral
hemorrhage. Only first-ever strokes were included in the
analyses. Hazard ratios were calculated by analyzing
natural log (ln)insulin, (ln)HOMA-IR, and glucose per stan-
dard deviation increase. To verify the (log-)linearity of as-
sociations, we also categorized the exposure levels in
quartiles using the lowest quartile as the reference category.
The linear trend across quartiles was tested by including
median values of quartile categories as a continuous vari-
able in the model. All analyses were adjusted for age and
sex (model 1) and additionally for age, sex, and a propensity
score that included the following potential confounders:
systolic blood pressure, blood pressure-lowering medication
use, serum total cholesterol level, high density lipoprotein
cholesterol level, triglyceride level, lipid-lowering medica-
tion use, current cigarette smoking, body mass index,
waist/hip ratio, and plasma von Willebrand factor level
(model 2) (21). The main reason to adjust for a propensity
score instead of individual covariates was that the number
of intracerebral hemorrhages in our study was small in
comparison to the number of potential confounders.
Missing values in covariates, which varied from 0.0% to
5.1% per variable, were imputed with a linear regression
model based on age and sex. All analyses were performed
by using PASW Statistics for Windows, version 17.0
(SPSS, Inc., Chicago, Illinois).
RESULTS
Baseline characteristics of the study population are
shown in Table 3. The median age was 67.9 years, and
57.6% were women. The pairwise Pearson correlation coef-
ficient for (ln)insulin and (ln)HOMA-IR was 0.99, indicat-
ing almost perfect linearity. Glucose and (ln)HOMA-IR
were only weakly correlated (r = 0.51), as were glucose and
(ln)insulin (r = 0.37).
During 42,806 person-years of follow-up (median: 8.6
years), 366 participants developed a first-ever stroke, which
was classified in 225 as cerebral infarction, in 42 as
Table 3. Baseline Characteristics of the Study Population
(n = 5,234), the Rotterdam Study, 1997–2008
Continuous Variables No. % Median IQR
Age, years 67.9 62.4–74.6
Systolic blood
pressure, mm Hg
140 127–155
Diastolic blood
pressure, mm Hg
76 69–84
Total cholesterol,
mmol/L
5.8 5.2–6.5
HDL cholesterol,
mmol/L
1.4 1.1–1.6
Triglycerides, mmol/L 1.3 1.0–1.8
Body mass indexa 26.3 24.1–28.9
Waist/hip ratio, cm/cm 0.92 0.84–0.98
Von Willebrand factor,
IU/mL
1.2 0.9–1.6
Glucose, mmol/L 5.5 5.2–5.9
Insulin, pmol/L 65 46–91
HOMA-IR index 2.3 1.6–3.3
Female sex 3,017 57.6
Current cigarette
smoking
908 17.5
Blood pressure-
lowering medication
1,599 32.2
Hypertension 3,337 65.3
Lipid-lowering
medication
592 11.9
Abbreviations: HDL, high density lipoprotein; HOMA-IR,
homeostasis model assessment for insulin resistance; IQR,
interquartile range.
a Body mass index: weight (kg)/height (m)2.
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intracerebral hemorrhage, and in 99 as unspecified. Table 4
shows the associations between the HOMA-IR index,
fasting insulin levels, and fasting glucose levels and risk of
any stroke. The HOMA-IR index and fasting insulin levels
were not associated with risk of stroke after adjustment for
age and sex (model 1). However, the HOMA-IR index and
insulin levels were borderline inversely associated with risk
of stroke after adjustment for multiple putative confounders
(model 2). Furthermore, the effect estimates for HOMA-IR
and insulin levels were practically identical, as could be ex-
pected given their high correlation. Fasting glucose levels
in the nondiabetic range were also not associated with risk
of stroke. However, because the pattern across glucose
quartiles seemed suggestive of a curvilinear relation, we ad-
ditionally performed a quadratic trend test, which did not
reach statistical significance at the conventional α = 0.05
level (P = 0.08).
Associations between insulin levels, the HOMA-IR
index, and glucose levels and the risk of stroke subtypes,
cerebral infarction and intracerebral hemorrhage, are shown
in Table 5. HOMA-IR and fasting insulin levels were not
associated with cerebral infarction after adjustment for age
and sex, but they were inversely associated with cerebral
infarction after adjustment for multiple confounders,
similar to what we found for any stroke. Fasting glucose
levels were not associated with risk of cerebral infarction in
either model. Table 5 further shows that neither fasting
insulin levels, nor HOMA-IR, nor fasting glucose levels
were associated with risk of intracerebral hemorrhage.
Because we did not observe any association between in-
creasing glucose or insulin levels and stroke, we checked in
a post-hoc analysis whether diabetes mellitus was associat-
ed with risk of stroke in our study cohort. For this purpose,
we added the participants with diabetes mellitus at baseline
(n = 635), whom we had excluded for the other analyses, to
the population for analysis, and we used Cox regression to
calculate the association between diabetes mellitus and risk
of stroke, adjusted for age, sex, and a propensity score of
potential confounders (models 1 and 2). Diabetes mellitus
was indeed associated with an increased risk of stroke,
Table 4. Associations of Insulin, HOMA-IR, and Glucose With Risk of Any Stroke, the Rotterdam Study, 1997–
2008
At Risk No.
of Events
Model 1a Model 2b
No. Person-Years HR 95% CI HR 95% CI
Insulin level, pmol/L
Per SDc 5,234 42,806 366 0.94 0.85, 1.05 0.86 0.76, 0.98
Quartile 1 (10–46) 1,318 10,747 94 1.00 Referent 1.00 Referent
Quartile 2 (47–64) 1,269 10,425 91 0.96 0.72, 1.28 0.91 0.68, 1.22
Quartile 3 (65–90) 1,338 11,038 94 0.98 0.74, 1.30 0.88 0.65, 1.19
Quartile 4 (91–430) 1,309 10,595 87 0.95 0.71, 1.27 0.80 0.57, 1.12
Ptrend 0.76 0.21
HOMA-IR
Per SDc 5,234 42,806 366 0.95 0.86, 1.06 0.86 0.76, 0.98
Quartile 1 (0.3–<1.6) 1,310 10,638 100 1.00 Referent 1.00 Referent
Quartile 2 (1.6–<2.3) 1,303 10,848 84 0.78 0.58, 1.04 0.73 0.54, 0.97
Quartile 3 (2.3–<3.3) 1,313 10,727 96 0.96 0.73, 1.28 0.84 0.62, 1.13
Quartile 4 (3.3–15.2) 1,308 10,592 86 0.86 0.64, 1.14 0.68 0.49, 0.96
Ptrend 0.59 0.08
Glucose level, mmol/L
Per SD 5,234 42,806 366 1.05 0.94, 1.16 1.00 0.90, 1.11
Quartile 1 (3.7–<5.2) 1,221 10,069 91 1.00 Referent 1.00 Referent
Quartile 2 (5.2–<5.5) 1,555 12,783 102 0.89 0.67, 1.18 0.86 0.65, 1.14
Quartile 3 (5.5–<5.9) 1,031 8,415 61 0.78 0.57, 1.08 0.73 0.52, 1.01
Quartile 4 (5.9–6.9) 1,427 11,539 112 1.06 0.80, 1.40 0.94 0.70, 1.26
Ptrend 0.69 0.65
Abbreviations: CI, confidence interval; HR, hazard ratio; HOMA-IR, homeostasis model assessment for insulin
resistance; SD, standard deviation.
a Model 1: adjusted for age and sex.
b Model 2: adjusted for age, sex, and a propensity score (current smoking, systolic blood pressure, blood
pressure-lowering medication use, total cholesterol, high density lipoprotein cholesterol, triglycerides, lipid-lowering
medication use, von Willebrand factor, body mass index, and waist/hip ratio).
c Insulin levels and the HOMA-IR index are natural log transformed.
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independent of confounders (hazard ratio = 1.59, 95% con-
fidence interval: 1.06, 2.40).
DISCUSSION
In this prospective population-based cohort study among
nondiabetic elderly people, we found no association
between insulin resistance markers and risk of stroke or the
stroke subtypes, cerebral infarction and intracerebral hemor-
rhage. We also confirmed previous findings that fasting
glucose levels below the diabetes threshold are not associat-
ed with risk of stroke or its subtypes.
We excluded diabetic elderly from the study population
because we aimed to study fasting insulin levels as a
marker of insulin resistance. Whereas fasting insulin levels
accurately reflect the degree of insulin resistance in people
without diabetes, in people with diabetes mellitus they do
not. Moreover, in people with diabetes mellitus, fasting
insulin levels may be low because of the combined effects
of insulin resistance and impaired insulin secretion.
Previous studies that investigated the association between
fasting insulin levels and stroke risk observed either border-
line significant associations or positive associations that
were strongly attenuated after adjustment for confounders,
particularly after adjustment for components of the meta-
bolic syndrome (8–10, 12, 13), though one study reported a
positive association that remained after adjustment for con-
founders (Table 1) (11). However, all studies but one were
conducted among middle-aged men and women (8, 10–13).
The only study carried out in an older population was re-
stricted to women and found no association (9). Our
finding that fasting insulin levels are not associated with
risk of stroke in elderly men and women adds to these pre-
vious findings and fits with prior knowledge of diabetes
mellitus being a stronger risk factor for stroke in younger
than in older people (4). The role of insulin resistance in
the elderly might be different from its role in middle-aged
or young people. We have tried to carefully adjust for con-
founding factors and cardiovascular risk factors. Neverthe-
less, we cannot completely rule out the possibility that
selective survival and mortality due to competing risks may
have influenced our results.
Associations between the HOMA-IR index and stroke
risk have also been investigated before (11, 14). Because
HOMA-IR was reported to correlate better with the eugly-
cemic hyperinsulinemic glucose clamp technique than
fasting insulin levels, recent epidemiologic studies tend to
use HOMA-IR as a marker for insulin resistance (6, 7).
However, in normoglycemic conditions, fasting insulin
levels also accurately reflect insulin resistance (7). There-
fore, it was not surprising that we observed an almost
perfect correlation between the fasting insulin level and the
HOMA-IR index (r = 0.99). Nonetheless, for the sake of
comparability with other studies, we present results for
both the HOMA-IR index and the fasting insulin level.
Three follow-up studies addressed the association between
HOMA-IR and stroke with conflicting results (Table 2).
One study found no association but was conducted in a
highly selected study population of people with preexisting
coronary heart disease (22). Two other studies, one of
which included only 13 events (11) and the other only 46
events (14), reported (borderline) positive associations.
However, because the effect estimates for successive
HOMA-IR quartiles in these studies were fluctuating,
the interpretation of these findings remains questionable.
We showed in the largest study so far that HOMA-IR, like
fasting insulin level, is not associated with stroke or
cerebral infarction. Furthermore, our study shows that, in
normoglycemic elderly, HOMA-IR does not provide any
additional information beyond that provided by the fasting
insulin level.
It should be noted that, though we found null associa-
tions between insulin and the HOMA-IR index and stroke
in minimally adjusted analyses, we found inverse associa-
tions when we adjusted for multiple putative confounders.
On the basis of prior knowledge, we consider a protective
effect of increasing insulin resistance on stroke risk highly
unlikely. Instead, we consider it more likely that the inverse
association is a spurious relation introduced after the adjust-
ment for strong confounders.
Because diabetes mellitus is associated with the risks of
both thromboembolic vascular disease and intracerebral
hemorrhage, we also investigated the relation between
insulin resistance markers and intracerebral hemorrhage (4).
We found that neither HOMA-IR nor fasting insulin levels
were associated with an increased risk. We are not aware of
any studies reporting on the association between HOMA-
IR or fasting insulin level and risk of intracerebral
Table 5. Associations of Insulin, HOMA-IR, and Glucose With Risk
of Cerebral Infarction and Intracerebral Hemorrhage, the Rotterdam
Study, 1997–2008
Model 1a Model 2b
HR 95% CI HR 95% CI
Cerebral infarction
(n = 225)
Insulin levelc per SD 0.92 0.81, 1.06 0.83 0.71, 0.98
HOMA-IR indexc per
SD
0.93 0.82, 1.06 0.83 0.71, 0.97
Glucose level per SD 1.02 0.90, 1.17 0.97 0.85, 1.12
Intracerebral
hemorrhage
(n = 42)
Insulin levelc per SD 1.00 0.73, 1.35 1.08 0.74, 1.55
HOMA-IR indexc per
SD
1.03 0.76, 1.39 1.11 0.76, 1.60
Glucose level per SD 1.19 0.89, 1.60 1.16 0.85, 1.59
Abbreviations: CI, confidence interval; HOMA-IR, homeostasis
model assessment for insulin resistance; HR, hazard ratio; SD,
standard deviation.
a Model 1: adjusted for age and sex.
b Model 2: adjusted for age, sex, and a propensity score (current
smoking, systolic blood pressure, blood pressure-lowering medication
use, total cholesterol, high density lipoprotein cholesterol, triglycerides,
lipid-lowering medication use, von Willebrand factor, body mass index,
and waist/hip ratio).
c Insulin levels and the HOMA-IR index are natural log
transformed.
Insulin Resistance and Risk of Stroke 705
Am J Epidemiol. 2012;176(8):699–707
 at Institute of Social Studies on A
ugust 11, 2015
http://aje.oxfordjournals.org/
D
ow
nloaded from
 
hemorrhage. Therefore, our study provides new information
that insulin resistance does not play a major role in the oc-
currence intracerebral hemorrhage. However, because our
results were based on only 42 intracerebral hemorrhages,
additional studies are needed to confirm these findings.
Diabetes mellitus is diagnosed if the fasting glucose
level exceeds 7.0 mmol/L (23). The rationale for this
threshold is that the presence of retinopathy lesions increas-
es at higher levels (23). The observation that diabetes mel-
litus and glucose levels above 7.0 mmol/L associate with
stroke risk, whereas precursor stages of diabetes do not, in-
dicates that a similar threshold may hold for stroke risk (4).
Besides, because the retinal microvasculature and the cere-
bral microvasculature have many characteristics in common
(24), it is not surprising that the deleterious effects of hy-
perglycemia, hyperinsulinemia, and insulin resistance start
at similar thresholds in both retinopathy and stroke.
We studied 2 markers of insulin resistance that are tradi-
tionally considered to reliably reflect the degree of insulin
resistance in people without diabetes mellitus, that is,
fasting insulin level and HOMA-IR. However, we note that
investigating postprandial insulin measurements and thus
postprandial insulin resistance would have been of addition-
al value, particularly because postprandial insulin measure-
ments were recently shown to associate with risk of stroke
in elderly persons (25). Unfortunately, in the present study
population, we did not have postprandial insulin measure-
ments. We have shown that fasting markers of insulin resis-
tance do not associate with stroke risk. Future studies
should further explore whether postprandial characteristics
of insulin resistance are better markers of stroke risk than
fasting characteristics.
Strengths of the study include the prospective and popula-
tion-based design, the large number of participants, and the
long duration and completeness of the follow-up. However,
this study also has some limitations. We did not include
2,477 participants in the analysis because of incomplete data
on fasting glucose levels or fasting insulin levels. These par-
ticipants were older (median age: 74.5 vs. 67.9 years) and
more often female (68% vs. 58%) in comparison to the study
population. Therefore, it is possible that exclusion of these
participants resulted in some selection bias. However, in lon-
gitudinal studies, a more important source of selection bias is
loss to follow-up, which was only 2.4% in this study.
Another consideration is that, inherent to the population-
based design and rigorous stroke monitoring procedure, neu-
roimaging had not been performed in all stroke cases. As a
result, 27% of the strokes could not be classified as either
cerebral infarction or intracerebral hemorrhage. However,
because the association between fasting insulin levels and un-
specified stroke risk (per standard deviation = 0.86, 95% CI:
0.68, 1.08 (Model 2)) was not materially different from the
association between insulin levels and cerebral infarction or
intracerebral hemorrhage (Table 4), we consider this misclas-
sification of limited importance. In addition, fasting insulin
levels were measured only once, so we could not investigate
whether results were influenced by intraindividual fluctua-
tions in insulin resistance.
To conclude, in this population-based cohort study
among nondiabetic elderly people, we found no evidence
for an association between markers of insulin resistance
and risk of any stroke, cerebral infarction, or intracerebral
hemorrhage. Taken together with previous findings that
fasting glucose levels below the diabetes threshold are not
associated with stroke risk (4), these results indicate that, in
contrast with overt diabetes mellitus, precursor stages of di-
abetes mellitus, as measured by fasting glucose levels,
fasting insulin levels, and the HOMA-IR index, do not
seem to be important risk factors for stroke, cerebral infarc-
tion, or intracerebral hemorrhage.
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